Adlai Nortye (NASDAQ:ANL) Sees Strong Trading Volume – Here’s Why

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) saw unusually-strong trading volume on Thursday. 622,510 shares traded hands during mid-day trading, an increase of 71% from the previous session’s volume of 363,053 shares. The stock last traded at $14.3780 and had previously closed at $14.05.

Wall Street Analysts Forecast Growth

ANL has been the subject of several research reports. Wall Street Zen upgraded shares of Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research note on Tuesday, July 14th. Jefferies Financial Group upgraded shares of Adlai Nortye to a “strong-buy” rating in a research report on Monday. Loop Capital set a $49.00 price target on shares of Adlai Nortye in a research note on Tuesday, September 8th. Finally, Cantor Fitzgerald initiated coverage on shares of Adlai Nortye in a report on Monday, June 22nd. They issued an “overweight” rating for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Adlai Nortye presently has an average rating of “Moderate Buy” and an average price target of $29.50.

Adlai Nortye Trading Up 2.7%

The firm has a 50-day simple moving average of $14.46 and a 200 day simple moving average of $12.45.

Insider Activity

In other news, Director Ping Ji sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the sale, the director directly owned 121,453 shares of the company’s stock, valued at $1,942,033.47. The trade was a 7.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Xiaofeng Ye sold 6,000 shares of the business’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $13.98, for a total value of $83,880.00. Following the completion of the sale, the chief financial officer directly owned 153,424 shares in the company, valued at $2,144,867.52. This trade represents a 3.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 26,881 shares of company stock valued at $411,060.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. SmartHarvest Portfolios LLC lifted its position in Adlai Nortye by 8.5% in the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after acquiring an additional 1,279 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Adlai Nortye during the first quarter valued at $457,000. ADAR1 Capital Management LLC bought a new position in Adlai Nortye in the first quarter valued at about $816,000. Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye in the 1st quarter worth approximately $1,140,000. Finally, Seven Fleet Capital Management LP bought a new position in Adlai Nortye in the second quarter worth approximately $1,302,000. Institutional investors own 35.21% of the company’s stock.

About Adlai Nortye

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.